- US-listed companies
- SOLENO THERAPEUTICS INC
- Balance sheet
SOLENO THERAPEUTICS INC (SLNO) Balance sheet
Market cap
$1.9B
P/E ratio
| 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Cash and cash equivalents | 8 | 5 | 3 | 17 | 23 | 21 | 49 | 21 | 15 | 170 | 88 |
| Marketable securities, current | - | - | - | - | - | - | - | - | - | - | 204 |
| Total cash & short-term investments | 8 | 5 | 3 | 17 | 23 | 21 | 49 | 21 | 15 | 170 | 291 |
| Accounts receivable, net | - | 156,127 | 133,337 | - | - | - | - | - | - | - | - |
| Inventories | 109,336 | 551,008 | 660,391 | - | - | - | - | - | - | - | - |
| Total current assets | 8 | 6 | 4 | 18 | 25 | 21 | 50 | 22 | 16 | 171 | 294 |
| Property, plant and equipment, net | 57,607 | 85,745 | 102,560 | 22,885 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Marketable securities, non-current | - | - | - | - | - | - | - | - | - | - | 27 |
| Total non-current assets | 57,607 | 2 | 2 | 21 | 18 | 17 | 15 | 13 | 11 | 9 | 37 |
| Total assets | 8 | 8 | 6 | 39 | 43 | 38 | 65 | 36 | 26 | 181 | 331 |
| Accounts payable | 986,799 | 695,056 | 537,891 | 633,104 | 1 | 2 | 3 | 3 | 2 | 3 | 9 |
| Total current liabilities | 1 | 3 | 2 | 2 | 2 | 5 | 9 | 8 | 7 | 12 | 19 |
| Long-term debt, non-current | - | - | - | - | - | - | - | - | - | - | 50 |
| Total non-current liabilities | - | - | 422,277 | 11 | 11 | 18 | 11 | 10 | 9 | 12 | 67 |
| Total liabilities | - | - | 2 | 12 | 13 | 23 | 19 | 18 | 16 | 23 | 86 |
| Common stock and paid-in capital | 6,769 | 14,018 | 3,357 | 19,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained earnings | -70,975,024 | -86,246,673 | -98,311,887 | -113,979,312 | -127 | -158 | -182 | -213 | -237 | -276 | -452 |
| Stockholders' equity | -10,332,591 | 3 | 3 | 27 | 30 | 15 | 46 | 18 | 10 | 158 | 245 |
| Total debt | - | - | - | - | - | - | - | - | - | - | 50 |
| Net debt | - | - | - | - | - | - | - | - | - | - | -242 |
| D/E ratio (%) | - | - | - | - | - | - | - | - | - | - | 20.3 |
| Working capital | - | - | - | - | - | - | - | - | - |